Biomarkers for the prediction and monitoring of the antipsychotic/antidepressant-induced hepatotoxicity: study protocol DOI Creative Commons
Zuzana Kilianova, Natália Stollárová, Lenka Bies Piváčková

и другие.

Pharmacogenomics, Год журнала: 2024, Номер 25(16-18), С. 667 - 678

Опубликована: Дек. 11, 2024

This study is designed to address the connection between antidepressant and antipsychotic-induced hepatotoxicity with pharmacogenetic epigenetic indicators, using a novel combined approach of CYP450 polymorphism determination early liver injury detection via microRNA testing. The multi-centric retrospective case-control in Slovakia involves 151 cases signs 604 controls without. Participants will be tested for selected CYP450, UGT1A1 polymorphisms, microRNAs. Anticipated findings test if patients specific polymorphisms are at higher risk drug-induced plasma microRNAs hsa-miR-122-5p hsa-miR-192-5p, alone or combined, can differentiate abnormal function. could contribute personalized treatment by combining genetic biomarkers.

Язык: Английский

Exploring perceived barriers and attitudes in young adults towards antidepressant pharmacotherapy, including the implementation of pharmacogenetic testing to optimize prescription practices DOI Creative Commons
Bradley Roberts, Zahra Cooper,

Georgia Landery

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 15

Опубликована: Янв. 3, 2025

The field of pharmacogenetics (PGx) is experiencing significant growth, with increasing evidence to support its application in psychiatric care, suggesting potential personalize treatment plans, optimize medication efficacy, and reduce adverse drug reactions. However, the perceived utility practicability PGx for youth remains underexplored. This study investigated barriers attitudes Australian young adults towards implementation testing guide antidepressant primary care. Semi-structured focus groups interviews were conducted 17 participants aged between 18 24 years. These sessions recorded transcribed before thematic analysis was used identify collective themes. Three key themes identified, including prescription process, concerns testing, clinical implementation. Although positively by most participants, all shared about testing. Participants voiced financial impact delays, accuracy guiding treatment. Additionally, noted that low awareness willingness general practitioners incorporate into routine practice could hinder successful Prior practices, it essential acknowledge patient perspectives ensure practices remain patient-focused. highlights important considerations integrating pharmacotherapy emphasizes need future research address mitigate adults.

Язык: Английский

Процитировано

0

Exploring Youth-Perceived Barriers and Attitudes Towards the Clinical Use of Pharmacogenetic Testing to Optimise Antidepressant Pharmacotherapy DOI Open Access
Bradley Roberts, Zahra Cooper,

Georgia Landery

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Авг. 26, 2024

Abstract The field of pharmacogenetics (PGx) is experiencing significant growth, with increasing evidence to support its application in psychiatric care, suggesting potential personalise treatment plans, optimise medication efficacy, and reduce adverse drug reactions. However, the perceived utility practicability PGx for youth remains underexplored. This study investigated youth-perceived barriers attitudes towards implementation testing guide antidepressant primary care. Semi-structured focus groups interviews were conducted 17 participants aged between 18 24 years. These sessions recorded transcribed before thematic analysis was used identify collective themes. Three key themes identified, including prescription process, concerns testing, clinical implementation. Although positively by most participants, all shared about testing. Participants voiced financial impact delays, accuracy guiding treatment. Additionally, noted that low awareness willingness general practitioners incorporate into routine practice could hinder successful Prior Australian practices, it essential acknowledge patient perspectives ensure practices remain patient-focused. highlights important considerations integrating pharmacotherapy emphasizes need future research address mitigate barriers.

Язык: Английский

Процитировано

0

Analysis of the current situation of pharmacogenomics in terms of educational and healthcare needs in Egypt and Lebanon DOI
Sahar M. El‐Gowilly, Heba A. Metwaly, Dalia Makhlouf

и другие.

Pharmacogenomics, Год журнала: 2024, Номер 25(10-11), С. 429 - 440

Опубликована: Июль 23, 2024

Pharmacogenomics (PGx) is a practice that investigates the link between genetic differences and drug response in patients. This can improve treatment effectiveness reduce harmful side effects. However, has yet to be adequately realized developing nations. Three surveys were conducted November 2022 March 2023 Egypt Lebanon. The first survey assessed availability of PGx testing different healthcare facilities; second one knowledge, interest attitude toward learning about among pharmacists physicians; third providing education at academic levels. In Egypt, few surveyed facilities are conducting some form pharmacogenetic testing. Lebanon, very germline pharmacogenomic tests offered Greater Beirut's leading hospitals, no other was recorded. attracts considerable interest, with 34.3% interested 48.8% interested. Similarly, 24.8% total physicians while 44.8% Academic professionals institutions both countries agreed on need for educational programs 78.2% there good opportunities implementing These findings clearly indicate develop implement Middle-East.

Язык: Английский

Процитировано

0

Genetic testing in psychiatry, the perceptions of healthcare workers and patients: a mini review DOI Creative Commons
Kyriakos Ioannou, Anastasia Constantinidou, Andreas Chatzittofis

и другие.

Frontiers in Public Health, Год журнала: 2024, Номер 12

Опубликована: Окт. 10, 2024

Background Genetic testing in psychiatry has gained attention, raising questions about its application and impact. Understanding stakeholders’ perspectives, including healthcare providers patients, is vital for informed policy development. The aim of this systematic review was to focus on the perceptions concerns patients workers regarding use genetic testing. Methods We conducted a following PRISMA guidelines, period 1/2/2014, 1/1/2024, via PubMed Embase databases identifying 50 articles total. After excluding duplicates ( n = 12), 38 went through screening. careful full-text article assessment eligibility applying inclusion exclusion criteria, only fifteen 15) were included. Results Among 15 selected studies involving 3,156 participants (2,347 professionals; 809 patients), thematic analysis identified four primary themes: Organizational-implementation concerns, Ethical Considerations, Concerns changes clinical praxis, Legal implications. Despite these seven out eleven indicated that viewed positively. Patients’ perspectives varied, with two reflecting positive attitudes. No pervasive negative sentiment observed. Conclusion Our highlights multidimensional professionals surrounding psychiatry. These considerations need be addressed facilitate implementation praxis Further research needed validation results guide policies clinicians integration into mental practice.

Язык: Английский

Процитировано

0

Pharmacogenomic testing and implications for psychiatric medication prescribing DOI
Rose Mary Xavier

The Nurse Practitioner, Год журнала: 2024, Номер 49(12), С. 24 - 33

Опубликована: Ноя. 21, 2024

ABSTRACT A pharmacogenomics-informed prescribing strategy examines genetic variations in individual patients for more personalized selection and dosing of psychiatric medications which a clinical evidence base and/or guidelines exist. Clinicians who prescribe should be aware the pharmacogenomic existing relevant to medication selection, dosing, interactions ensure safe effective treatment. Although testing does not replace current strategies, when used alongside them, it acts as valuable decision support tool that can improve specific medications.

Язык: Английский

Процитировано

0

Biomarkers for the prediction and monitoring of the antipsychotic/antidepressant-induced hepatotoxicity: study protocol DOI Creative Commons
Zuzana Kilianova, Natália Stollárová, Lenka Bies Piváčková

и другие.

Pharmacogenomics, Год журнала: 2024, Номер 25(16-18), С. 667 - 678

Опубликована: Дек. 11, 2024

This study is designed to address the connection between antidepressant and antipsychotic-induced hepatotoxicity with pharmacogenetic epigenetic indicators, using a novel combined approach of CYP450 polymorphism determination early liver injury detection via microRNA testing. The multi-centric retrospective case-control in Slovakia involves 151 cases signs 604 controls without. Participants will be tested for selected CYP450, UGT1A1 polymorphisms, microRNAs. Anticipated findings test if patients specific polymorphisms are at higher risk drug-induced plasma microRNAs hsa-miR-122-5p hsa-miR-192-5p, alone or combined, can differentiate abnormal function. could contribute personalized treatment by combining genetic biomarkers.

Язык: Английский

Процитировано

0